



Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis

Guest Editors:

Dr. Stefano Indraccolo

Immunology and Molecular
Oncology Unit, Veneto Institute
of Oncology IOV—IRCCS, 35128
Padova, Italy

Dr. Paola Ulivi

Biosciences Laboratory, IRCCS
Istituto Romagnolo per lo Studio
dei Tumori “Dino Amadori”
(IRST), via P. Maroncelli 40, 47014
Meldola, Italy

Deadline for manuscript
submissions:

closed (15 February 2022)

Message from the Guest Editors

Liquid biopsy has emerged as new tool for detecting clinically relevant genetic alterations in cancer patients. The term liquid biopsy is commonly used not only to refer to molecular assays performed on cell-free DNA purified from plasma but can also include testing on other body fluids, such as urine and cerebrospinal fluid and measurements of circulating tumor cells, exosomes and circulating tumor RNA.

Here, we would like to focus on liquid biopsy approaches to track response to therapy in solid tumors. This special issue will cover studies investigating the significance of liquid biopsy for diagnostic/prognostic purposes as well as to predict patient outcome, compared with patient management guided via canonical molecular data and imaging modalities.

In this Special Issue, we welcome Original Research and Review articles focused on, but not limited to, dynamic measurements of mutations and other genetic alterations in plasma or other fluids. Studies on other liquid biopsy biomarkers such as microRNA and proteins are also considered.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)